Ascendis Pharma ADR (ASND)

$173.69 -0.71 (-0.41%)
Market Cap 9.93B
Revenue (ttm) 393.50M
Net Income (ttm) -409.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -103.97%
Debt to Equity Ratio -4.46
Volume 537,000
Avg Vol 515,852
Day's Range N/A - N/A
Shares Out 60.97M
Stochastic %K 91%
Beta 0.41
Analysts Strong Sell
Price Target $220.06

Latest News on ASND

FDA Accepts TransCon® CNP NDA for Priority Review

Jun 2, 2025, 8:00 AM EDT - 2 days ago

FDA Accepts TransCon® CNP NDA for Priority Review

Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction

May 20, 2025, 6:00 AM EDT - 15 days ago

Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

May 13, 2025, 4:01 PM EDT - 22 days ago

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

May 12, 2025, 4:45 PM EDT - 23 days ago

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

May 5, 2025, 8:30 AM EDT - 4 weeks ago

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript

May 1, 2025, 9:35 PM EDT - 4 weeks ago

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript

Ascendis Pharma Reports First Quarter 2025 Financial Results

May 1, 2025, 4:01 PM EDT - 4 weeks ago

Ascendis Pharma Reports First Quarter 2025 Financial Results

Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025

Apr 24, 2025, 4:01 PM EDT - 5 weeks ago

Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory

Apr 14, 2025, 4:38 PM EDT - 7 weeks ago

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

Mar 31, 2025, 4:01 PM EDT - 2 months ago

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 4:01 PM EST - 3 months ago

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?

Feb 13, 2025, 2:40 PM EST - 3 months ago

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?

Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 11:03 PM EST - 4 months ago

Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

Feb 12, 2025, 4:05 PM EST - 4 months ago

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 12, 2025, 4:01 PM EST - 4 months ago

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

Feb 5, 2025, 4:01 PM EST - 4 months ago

Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

Ascendis-Novo Weight Loss Deal Highlights Technology Platform, Signals Growth Potential (Rating Upgrade)

Jan 29, 2025, 11:25 AM EST - 4 months ago

Ascendis-Novo Weight Loss Deal Highlights Technology Platform, Signals Growth Potential (Rating Upgrade)

Ascendis Pharma: Danish Blockbuster Hunter

Jan 29, 2025, 12:31 AM EST - 4 months ago

Ascendis Pharma: Danish Blockbuster Hunter

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

Jan 12, 2025, 5:00 PM EST - 5 months ago

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:30 AM EST - 5 months ago

Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

Dec 19, 2024, 8:30 AM EST - 5 months ago

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

Dec 16, 2024, 8:30 AM EST - 6 months ago

New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

FDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

Dec 12, 2024, 4:01 PM EST - 6 months ago

FDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian Markets

Dec 10, 2024, 7:00 AM EST - 6 months ago

Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian Markets

Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 10:53 PM EST - 7 months ago

Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript

Ascendis Pharma Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 4:01 PM EST - 7 months ago

Ascendis Pharma Reports Third Quarter 2024 Financial Results

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

Sep 30, 2024, 8:30 AM EDT - 8 months ago

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

Sep 30, 2024, 8:30 AM EDT - 8 months ago

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

Sep 19, 2024, 8:16 PM EDT - 9 months ago

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Sep 18, 2024, 4:04 PM EDT - 9 months ago

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year

Sep 16, 2024, 12:18 PM EDT - 9 months ago

Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year

Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Sep 16, 2024, 7:00 AM EDT - 9 months ago

Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024

Sep 13, 2024, 8:30 AM EDT - 9 months ago

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024

Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

Sep 11, 2024, 5:37 PM EDT - 9 months ago

Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

Ascendis Pharma Takes A Big Price Cut On Skytrofa

Sep 5, 2024, 1:30 AM EDT - 9 months ago

Ascendis Pharma Takes A Big Price Cut On Skytrofa

Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In

Sep 4, 2024, 5:02 PM EDT - 9 months ago

Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In

Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut

Sep 4, 2024, 9:09 AM EDT - 9 months ago

Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut

Ascendis Pharma A/S (ASND) Q2 2024 Earnings Call Transcript

Sep 3, 2024, 9:41 PM EDT - 9 months ago

Ascendis Pharma A/S (ASND) Q2 2024 Earnings Call Transcript

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

Sep 3, 2024, 5:06 PM EDT - 9 months ago

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

Ascendis Pharma Reports Second Quarter 2024 Financial Results

Sep 3, 2024, 5:04 PM EDT - 9 months ago

Ascendis Pharma Reports Second Quarter 2024 Financial Results

Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024

Aug 28, 2024, 8:30 AM EDT - 10 months ago

Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024

Ascendis Pharma: Yorvipath Approved, Launch Delayed, Many Other Updates Coming Up

Aug 13, 2024, 5:25 AM EDT - 10 months ago

Ascendis Pharma: Yorvipath Approved, Launch Delayed, Many Other Updates Coming Up

Ascendis Pharma's stock surges after FDA approval for first and only treatment for rare disease

Aug 12, 2024, 8:51 AM EDT - 10 months ago

Ascendis Pharma's stock surges after FDA approval for first and only treatment for rare disease

FDA approves Ascendis Pharma's hormone disorder therapy

Aug 12, 2024, 7:23 AM EDT - 10 months ago

FDA approves Ascendis Pharma's hormone disorder therapy

Weaker USD, Revenue Growth, And TransCon Technology Make Ascendis Pharma A Strong Buy Opportunity

Jul 29, 2024, 5:52 AM EDT - 11 months ago

Weaker USD, Revenue Growth, And TransCon Technology Make Ascendis Pharma A Strong Buy Opportunity

Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024

Jun 24, 2024, 4:45 PM EDT - 1 year ago

Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024

Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 4, 2024, 4:01 PM EDT - 1 year ago

Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

Jun 3, 2024, 4:01 PM EDT - 1 year ago

Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024

May 30, 2024, 8:30 AM EDT - 1 year ago

Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024

FDA extends review of Ascendis Pharma's hormone disorder therapy

May 14, 2024, 2:43 PM EDT - 1 year ago

FDA extends review of Ascendis Pharma's hormone disorder therapy